PAVmed reports Q1 2024 net loss of $22.8M; EsoGuard revenue flat QoQ at $1.0M

PAVmed Inc.

2024-Q1 EPS reported -$2.62 revenue$1,000,000

GAAP net loss $22.8M ($2.62 per share); non-GAAP adjusted loss $8.6M ($0.99 per share).
EsoGuard revenue $1.0M (flat vs Q4 2023, +124% YoY); operating expenses $15.0M.
Lucid completed $29.8M Series B Preferred Stock offering to strengthen balance sheet.
Secured July 17, 2024 MolDX pre-submission meeting for technical assessment under LCD.
Veris Health completed MOU with Ohio State's James Cancer Hospital for pilot program.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PAVmed Inc. reported three months ended March 31, 2024 results: revenue $1.0 million, net income $22.8 million, EPS $(2.62) per common share.

Period: three months ended March 31, 2024
Revenue: $1.0 million
Net income: $22.8 million
EPS: $(2.62) per common share
Result: reported results

Exact text from the filing

well in furtherance of this revised strategy.” Highlights from the first quarter and recent weeks include : ● Yesterday, Lucid reported that 1Q24 EsoGuard ® revenue was $1.0 million, which was flat compared to 4Q23 and represents a 124 percent increase from 1Q23. ● Strengthened balance sheet by Lucid’s completion of a $29.8 million Series B Preferred Stock

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.